AB 1864 creates a state-level obligation for companies that manufacture or supply gene synthesis — specifically benchtop nucleic acid synthesizers and certain synthetic nucleic acids — to operate under an established nucleic acid screening standard. The bill anchors compliance to the National Science and Technology Council’s Framework for Nucleic Acid Synthesis Screening (revised September 2024), while giving California’s State Department of Public Health authority to adopt alternative federal standards it finds equally or more protective and not unduly burdensome.
The statute is a targeted regulatory approach: it aims to reduce the biohazard risk from reckless or malicious use of synthesized nucleic acids by forcing vendors to screen orders and equipment against harmful sequences or customers. The bill also builds in rulemaking flexibility for state officials and declares the measure severable so remaining provisions survive if part is invalidated.
At a Glance
What It Does
Creates a requirement that manufacturers of benchtop nucleic acid synthesis equipment and providers of certain synthetic nucleic acids adhere to an established nucleic acid screening framework when producing or supplying those items to customers in California, unless the State Department of Public Health adopts a different federal standard by regulation.
Who It Affects
Manufacturers that produce benchtop nucleic acid synthesis equipment, commercial gene synthesis providers that supply synthetic nucleic acids subject to screening, and vendors (in‑state or out‑of‑state) selling or delivering those products to California customers; downstream buyers such as research labs and startups will face the compliance consequences in procurement.
Why It Matters
By tying California compliance to a federal screening framework (or an approved federal alternative), the bill would create a de facto regulatory baseline for gene synthesis screening in the state, changing vendor obligations, purchasing decisions, and supply‑chain risk management for biotech actors operating in or into California.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill makes two core operational moves. First, it obligates manufacturers of benchtop nucleic acid synthesis equipment and providers of synthetic nucleic acids subject to screening to ensure that the items they produce, sell, or deliver to customers in California meet a defined screening standard.
The statute incorporates the NSTC Fast Track Action Committee’s Framework for Nucleic Acid Synthesis Screening (revised September 2024) as the default standard, but it also authorizes the State Department of Public Health (DPH) to swap in one or more federal laws, regulations, or guidance documents instead, provided DPH judges those alternatives to give equal or greater protection and not impose unreasonable burdens on vendors.
The bill ties the operative obligations to activities: it covers production in California and sales or deliveries to customers located in California. The text also imports the framework’s defined terms (for example, manufacturer, provider, customer, and the specific class of "synthetic nucleic acids subject to screening") unless and until DPH uses its rulemaking authority to adopt alternate definitions alongside any alternative federal framework it selects.
As a practical matter, that means the legal scope — what sequences are covered, what constitutes a customer, and what counts as benchtop equipment — will track the underlying framework’s technical definitions unless DPH decides otherwise.Two drafting conventions matter for compliance: the bill converts normative language from the framework into legal obligations by specifying that where the framework says a vendor "should" do something, the statute treats that as a requirement; where the framework says a vendor is "encouraged" to do something, the statute treats that as a recommendation only. That mapping pulls into mandatory law many of the framework’s formerly optional practices and leaves others as nonbinding best practices.Finally, the bill gives DPH a rulemaking path to harmonize state requirements with federal instruments and to reconcile differing term definitions.
If DPH adopts regulations under that authority, the statute requires the department to report to the Legislature within one year evaluating whether the adopted regulations maintained or improved protection for Californians from relevant biohazards. The chapter is declared severable so remaining provisions can survive a court ruling invalidating part of the law.
The Five Things You Need to Know
The statutory duty applies when a vendor produces in California or sells or delivers covered equipment or sequences to a customer physically located in California — it is not limited to in‑state manufacturers.
If the framework’s text uses the word "should," AB 1864 treats that as a legal requirement for manufacturers and providers; language labeled "encouraged" in the framework remains nonbinding guidance.
The State Department of Public Health may replace the default framework with one or more federal law, regulation, or guidance documents by regulation if DPH finds they provide equal or greater protection and do not impose unreasonable burdens on vendors.
The Attorney General is the only entity authorized to bring a civil action to recover civil penalties for violations under this chapter.
A violator may face a civil penalty not to exceed $1,000 per day for each day the violation continues.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Definitions and default framework
This section sets the default meaning of "framework" as the NSTC Fast Track Action Committee’s Framework for Nucleic Acid Synthesis Screening (Sept 2024) unless the State Department of Public Health adopts regulations naming a different federal document. It also imports (by reference) key technical terms from that framework — for example, benchtop nucleic acid synthesis equipment, manufacturer, provider, customer, and the covered class of synthetic nucleic acids — but gives DPH the authority to redefine those terms if it adopts an alternative framework by regulation. Practically, this ties the statute’s reach and technical definitions to whatever screening standard DPH approves.
Operating prohibition tied to adherence
Section 24201 contains the operative prohibitions: a manufacturer may not produce benchtop nucleic acid synthesis equipment in California or sell/deliver that equipment to a California customer unless it adheres to the defined framework; likewise a provider may not produce or sell/deliver covered synthetic nucleic acids into California unless it adheres to the framework. The section also instructs that where the framework uses normative language, the statute treats "should" as mandatory and "encouraged" as advisory. This is the compliance hook: vendors must adopt the screening controls and procedures the chosen framework makes mandatory.
Civil penalties and enforcement
This section creates a civil penalty scheme: violations are subject to monetary penalties up to $1,000 per day that the violation continues. It further restricts enforcement to civil actions brought by the California Attorney General; private parties and local agencies do not have a private right to sue under this chapter. The framework does not describe an administrative inspection or certification process — the statute relies on civil enforcement rather than an explicit licensing or permitting regime.
State Department of Public Health rulemaking and reporting
Section 24203 authorizes DPH to adopt regulations that substitute one or more federal laws, regulations, or guidance documents for the default framework, provided DPH finds that substitution yields equal or greater biohazard protection and does not create unreasonable vendor burdens. The section allows DPH to map or identify functionally equivalent terms when definitions differ across documents and to revert to prior framework definitions where a federal document omits a term. If DPH issues any such regulations, it must report back to the Legislature within one year evaluating whether the regulations maintained or enhanced protection for Californians.
Severability
A standard severability clause ensures that if any provision of the chapter is invalidated in court, the remaining provisions remain in force to the extent they can operate without the invalidated part.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- California residents and public health authorities — the screening requirement aims to reduce the risk that dangerous nucleic acids are synthesized or supplied into the state, lowering the likelihood of accidental or malicious biohazard events.
- Responsible manufacturers and providers that already implement the NSTC framework — they gain legal clarity and a competitive advantage because compliance becomes a market requirement for selling into California.
- Large institutional purchasers (major universities, hospitals, and commercial labs) — by pushing vendors toward standardized screening, the bill can reduce their procurement risk and simplify vendor assessments.
Who Bears the Cost
- Benchtop nucleic acid synthesis equipment manufacturers and commercial gene synthesis providers — they must implement and maintain screening systems, adjust ordering workflows, and document compliance; these are operational and engineering costs that may be substantial for smaller firms.
- Small academic labs and biotech startups purchasing equipment or ordering sequences — increased screening may delay deliveries, raise costs, or restrict access to certain sequences or devices, affecting research timelines and budgets.
- California Department of Public Health and the Attorney General’s office — DPH will need staff time to evaluate federal documents, adopt regulations, and prepare the required report; the AG’s office will incur enforcement costs related to monitoring and litigation.
Key Issues
The Core Tension
The central dilemma is classic: increase biosecurity by making screening mandatory, which reduces risk but imposes compliance costs and may limit access to equipment and sequences that enable legitimate research and commercial activity; the statute aims to thread that needle by anchoring to a federal framework while delegating technical and definitional choices to state regulators, but delegating those choices shifts the burden and uncertainty onto vendors and regulated users.
The bill ties California compliance to an external technical framework but leaves crucial implementation choices to the State Department of Public Health. That choice creates both flexibility and uncertainty: vendors cannot fully predict their obligations until DPH either leaves the NSTC framework in place or adopts an alternative federal instrument and issues definitions by regulation.
The statute’s conversion of the framework’s "should" language into legal requirements pulls voluntary best practices into mandatory compliance, which raises questions about what constitutes a practicable compliance timeline and how DPH will interpret optional technical recommendations when enforcing the statute.
Enforcement design raises additional tradeoffs. The law limits enforcement to civil actions by the Attorney General and caps penalties at $1,000 per day.
That structure centralizes enforcement but may leave gaps: routine compliance monitoring, technical audits, and rapid corrective action are not described in the statute, and the penalty cap may be modest relative to the commercial value at stake or to the cost of prolonged noncompliance. The bill also does not address operational issues the screening process creates — for example, whether providers must transmit proprietary sequence or customer data to third‑party screening services, how to handle false positives that block legitimate research, or how vendors should certify and document adherence in practice.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.